How big is The Joint Corp. (United States)?

As of Jun 18, The Joint Corp. has a market capitalization of 168.99 million, with net sales of 87.99 million and a net profit of -6.29 million over the last four quarters.

Market Cap: As of Jun 18, The Joint Corp. (United States) has a market capitalization of 168.99 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, The Joint Corp. reported net sales of 87.99 million and a net profit of -6.29 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 17.92 million and total assets of 80.42 million.

What does The Joint Corp. (United States) do?

The Joint Corp. operates and manages chiropractic clinics in the U.S. as part of the Pharmaceuticals & Biotechnology industry, with a market cap of approximately $169 million and reported net sales of $13 million for Q1 2025.

Overview: <BR>The Joint Corp. (United States) develops, owns, operates, supports, and manages chiropractic clinics and belongs to the Pharmaceuticals & Biotechnology industry within the micro-cap market.<BR><BR>Financial Snapshot: <BR>Net Sales: 13 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 168.99 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.14 <BR>Return on Equity: -28.80% <BR>Price to Book: 8.49<BR><BR>Contact Details: <BR>Address: 16767 N PERIMETER DRIVE, SUITE 110, SCOTTSDALE AZ : 85260 <BR>Tel: ['1 480 2455960', '1 415 4333777'] <BR>Fax: 1 480 5137989 <BR>Website: https://www.thejoint.com/

Should I buy, sell or hold The Joint Corp. (United States)?

Who are in the management team of The Joint Corp. (United States)?

As of March 2022, The Joint Corp.'s management team includes President and CEO Peter Holt, Lead Independent Director Matthew Rubel, and Independent Directors James Amos, Ronald DaVella, Suzanne Decker, and Abe Hong, who oversee the company's operations and strategy.

As of March 2022, the management team of The Joint Corp. (United States) includes the following individuals:<BR><BR>- Mr. Peter Holt, who serves as the President, Chief Executive Officer, and Director.<BR>- Mr. Matthew Rubel, who is the Lead Independent Director.<BR>- Mr. James Amos, an Independent Director.<BR>- Mr. Ronald DaVella, an Independent Director.<BR>- Ms. Suzanne Decker, an Independent Director.<BR>- Mr. Abe Hong, an Independent Director. <BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Is The Joint Corp. (United States) overvalued or undervalued?

As of March 7, 2024, The Joint Corp. is considered overvalued with a risky valuation grade, reflected by a Price to Book Value of 9.25, an EV to EBITDA of 56.15, and a negative ROE of -28.80%, while its stock has underperformed the S&P 500 with a 1-year return of -10.55% and a 5-year return of -42.20%.

As of 7 March 2024, The Joint Corp. has moved from an attractive to a risky valuation grade. This indicates that the company is currently overvalued. Key ratios include a Price to Book Value of 9.25, an EV to EBITDA of 56.15, and a negative ROE of -28.80%. In comparison, Nutex Health, Inc. is rated very attractive with a P/E of 3.08 and an EV to EBITDA of 1.88, while LifeMD, Inc. is also risky with an EV to EBITDA of 31.81.<BR><BR>The company's stock has underperformed against the S&P 500, with a 1-year return of -10.55% compared to the index's 17.14%, and a 5-year return of -42.20% versus 96.61% for the S&P 500. This further reinforces the notion that The Joint Corp. is overvalued in its current market position.

Is The Joint Corp. (United States) technically bullish or bearish?

As of September 11, 2025, The Joint Corp. is in a mildly bearish trend, indicated by bearish MACD and moving averages, underperforming the S&P 500 with a year-to-date return of -3.48% compared to 12.22%.

As of 11 September 2025, the technical trend for The Joint Corp. has changed from sideways to mildly bearish. The current stance is bearish, with key indicators supporting this view including a bearish MACD on the weekly timeframe, bearish moving averages on the daily, and a mildly bearish signal from Bollinger Bands on the weekly. Additionally, the Dow Theory indicates a mildly bearish trend on both weekly and monthly timeframes. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a year-to-date return of -3.48% compared to the S&P 500's 12.22%, and a one-year return of -10.55% versus the S&P 500's 17.14%.